ilepatril
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
1
Phase 4
0
Earliest trial started Dec 1, 2005 (NCT00284128)
Timeline
2000s
- Jan 1, 2005
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Angiotensin-converting enzyme 2INHIBITOR
ACE2 inhibitor
- Angiotensin-converting enzymeINHIBITOR
Angiotensin-converting enzyme inhibitor
- NeprilysinINHIBITOR
Neprilysin inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC(=O)S[C@H](C(=O)N[C@H]1Cc2ccccc2[C@H]2CCC[C@@H](C(=O)O)N2C1=O)C(C)C- Mol. weight
- 432.54 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3187812 ↗
Also known as
- 7-(((2s)-2-(acetylthio)-1-oxo-3-methylpropyl)amino)-1,2,3,4,6,7,8,12b-octahydro-6-oxo-, (4s,7s,12br)-pyrido(2,1-a)(2)benzazepin-4-carboxy-acid
- ave7688
- ave7688
- ave7688
- ave 7688
- ilepatril
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00284128 | Phase 2/Phase 3 (Phase 3) | Dec 1, 2005 | Sanofi |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sanofi | For profit | 1 | 1 | 1 | 2005 |
1 organizations
Page 1 / 1